Research Article
Volume 9 Issue 3 - 2022
Malignancy Risk and Safety Issues of Azathioprine in Patients with Inflammatory Bowel Disease: Clinical Experience from a Referral Center
Georgios Kourtis1, Fotios S Fousekis2, Ioannis V Mitselos2, Maria Saridi3*, Eleni Albani4, Konstantinos Vlachos5, Konstantinos H Katsanos2 and Dimitrios K Christodoulou2
1Department of Nursing, General Hospital “Sotiria”, Athens, Greece
2Department of Gastroenterology, University Hospital of Ioannina, Ioannina, Greece
3General Department, University of Thessaly, Lamia, Greece
4Department of Nursing, University of Patra, Patra, Greece
5Department of Surgery, University Hospital of Ioannina, Ioannina, Greece
*Corresponding Author: Maria Saridi, General Department, University of Thessaly, Lamia, Greece.
Received: February 06, 2022; Published: February 25, 2022




Abstract

Background: Despite the development of new agents for the treatment of inflammatory bowel disease (IBD), azathioprine (AZA) is widely used as monotherapy or combination therapy for the induction and maintenance of remission in both Crohn’s disease (CD) and ulcerative colitis (UC). The aim of this study was to investigate both the prevalence of malignancy development in IBD patients receiving AZA as well as long-term safety of AZA and the management of adverse events.
Methods: Data were retrospectively extracted from the patient records of the Gastroenterology Department of University hospital of Ioannina from 2003 to 2019.
Results: 222 IBD patients treated with AZA, under regular follow-up intervals were included in the study. 65.6% of IBD patients (146/222) had CD and 34.4% had UC (76/222). The mean duration of AZA administration was 51 months (range: 0-135 months). The most common dose of AZA was 100mg/day (range: 50-200mg). The most common adverse events were gastrointestinal symptoms (8.6%, 18/222), leucopenia (2.7%, 6/222), hepatotoxicity (5.4%, 12/222) and pancreatitis (1.8%, 4/222). Two patients were diagnosed with basal cell cancer, while no hematological malignancy was detected. Infections were recorded in 19 patients (8.6%) of whom 6 needed hospitalization.          
Conclusion: According to this retrospective observational study, approximately one-third of IBD patients receiving AZA presented clinical significant adverse event during follow-up. Azathioprine withdrawal or dose reduction was needed in 47 (21%) patients.

 

Keywords: Azathioprine; Safety; Thiopurine; Inflammatory Bowel Disease; Ulcerative Colitis; Crohn’s Disease

References

  1. Torres J., et al. “ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment”. Journal of Crohn's and Colitis1 (2020): 4-22.
  2. Raine T., et al. “ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment”. Journal of Crohn's and Colitis (2021).
  3. Jong DJd., et al. “Safety of thiopurines in the treatment of inflammatory bowel disease”. Scandinavian Journal of Gastroenterology 38 (2003): 69-72.
  4. De Boer NKH., et al. “Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD”. Nature Clinical Practice Gastroenterology and Hepatology12 (2007): 686-694.
  5. Gisbert JP., et al. “Thiopurine Methyltransferase (TPMT) Activity and Adverse Effects of Azathioprine in Inflammatory Bowel Disease: Long-Term Follow-Up Study of 394 Patients”. The American journal of Gastroenterology12 (2006): 2769-2776.
  6. Goel RM, Blaker P., et al. “Optimizing the use of thiopurines in inflammatory bowel disease”. Therapeutic Advances in Chronic Disease3 (2015): 138-146.
  7. Pasternak B., et al. “Use of Azathioprine and the Risk of Cancer in Inflammatory Bowel Disease”. American Journal of Epidemiology11 (2013): 1296-1305.
  8. Wisniewski A., et al. “Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines”. United European Gastroenterology Journal3 (2020): 303-313.
  9. Lorenzetti R., et al. “Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials”. Annals of Medicine7 (2014): 547-554.
  10. Moran GW. “Clinical predictors of thiopurine-related adverse events in Crohn's disease”. World Journal of Gastroenterology25 (2015): 7795.
  11. Chaparro M., et al. “Safety of Thiopurine Therapy in Inflammatory Bowel Disease”. Inflammatory Bowel Diseases7 (2013): 1404-1410.
  12. McGovern DPB., et al. “Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity”. Gastroenterology3 (2002): 838-839.
  13. Gisbert JP and Gomolln F. “Thiopurine-Induced Myelotoxicity in Patients With Inflammatory Bowel Disease: A Review”. The American Journal of Gastroenterology7 (2008): 1783-1800.
  14. De Boer NKH., et al. “Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives”. Journal of Crohn's and Colitis5 (2018): 610-620.
  15. Calabrese E and Hanauer SB. “Assessment of non-cirrhotic portal hypertension associated with thiopurine therapy in inflammatory bowel disease”. Journal of Crohn's and Colitis1 (2011): 48-53.
  16. Fousekis FS., et al. “Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review”. Gastroenterology Research2 (2018): 83-94.
  17. Fousekis FS., et al. “Pancreatic Involvement in Inflammatory Bowel Disease: A Review”. Journal of Clinical Medicine Research10 (2018): 743-751.
  18. Bermejo F., et al. “Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis”. Alimentary Pharmacology and Therapeutics5 (2008): 623-628.
  19. Teich N., et al. “Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases-A Prospective Study on Incidence and Severity”. Journal of Crohn's and Colitis1 (2016): 61-68.
  20. Kirchgesner J., et al. “Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases”. Gastroenterology2 (2018): 337-346.
  21. Ardizzone S., et al. “Review: Immunomodulators for all patients with inflammatory bowel disease?” Therapeutic Advances in Gastroenterology1 (2010): 31-42.
  22. Ungaro RC., et al. “Effect of IBD medications on COVID-19 outcomes: results from an international registry”. Gut4 (2021): 725-732.
  23. Annese V., et al. “Impact of New Treatments on Hospitalisation, Surgery, Infection, and Mortality in IBD: a Focus Paper by the Epidemiology Committee of ECCO”. Journal of Crohn's and Colitis2 (2016): 216-225.
  24. Nakase H., et al. “Evidence-based clinical practice guidelines for inflammatory bowel disease 2020”. Journal of Gastroenterology6 (2021): 489-526.
  25. Huang S-Z., et al. “Risk of skin cancers in thiopurines-treated and thiopurines-untreated patients with inflammatory bowel disease: A systematic review and meta-analysis”. Journal of Gastroenterology and Hepatology3 (2019): 507-516.
  26. Kopylov U., et al. “Risk of Lymphoma, Colorectal and Skin Cancer in Patients with IBD Treated with Immunomodulators and Biologics”. Inflammatory Bowel Diseases8 (2015): 1847-1853.
  27. Hagen JW and Pugliano-Mauro MA. “Nonmelanoma Skin Cancer Risk in Patients With Inflammatory Bowel Disease Undergoing Thiopurine Therapy: A Systematic Review of the Literature”. Dermatologic Surgery4 (2018): 469-480.
  28. Giagkou E., et al. “Dermal Lesions and Skin Cancer in Patients with Inflammatory Bowel Disease Receiving Immunosuppressive Therapy”. Asian Pacific Journal of Cancer Prevention: APJCP10 (2018): 2845-2851.
  29. Nomura H., et al. “Azathioprine-induced alopecia and leukopenia associated with NUDT15 polymorphisms”. Journal of the European Academy of Dermatology and Venereology10 (2018): e386-e389.
Citation: Maria Saridi., et al. “Malignancy Risk and Safety Issues of Azathioprine in Patients with Inflammatory Bowel Disease: Clinical Experience from a Referral Center”. EC Gastroenterology and Digestive System 9.3 (2022): 17-25.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


December Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the November issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before December 23, 2022.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.